Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); WORLD 2012: Tali Safety Detail Continues to Support Approval

Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX) price target of $8.00.

Analyst, Ritu Baral, said, "We see good chance of May 2012 taliglucerase US approval, Q2/12 US launch, mid--2012 EU approval. We think PLX’s taliglucerase (tali) will finally be approved on its May 2012 PDUFA date. We think tali may get ~15% of the $1.2B+ worldwide Gaucher’s market, with an ex-US competitive pricing focus given resolution of the US Gaucher’s ERT shortage."

For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.

Shares of Protalix BioTherapeutics closed at $6.40 yesterday, with a 52 week range of $4.06-$9.84.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Barclays Maintains an 'Overweight' on Tidewater (TDW); Dayrates Climb, But Adjusting Numbers Lower on Expenses
• Barclays Cuts Estimates on Lowe's (LOW); Gross Margins Under Pressure; Performance Lags HD
• UBS Lowers Estimates and PT on Lowe's (LOW) Messy Q1, But Bullish Case Remains

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Genuity Capital Markets

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter